A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma.

Trial Profile

A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Rocapuldencel-T (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Argos Therapeutics Inc
  • Most Recent Events

    • 07 Mar 2010 Results of this trial were present at the ASCO Genitourinary Cancers Symposium 2010.
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top